ReviewFrontiers in immunology2026

Depemokimab and the twice-yearly regimen: pharmacological implications and therapeutic positioning in severe eosinophilic respiratory diseases.

A M Marra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.